2. Anti-infection Metabolic Enzyme/Protease Cell Cycle/DNA Damage
  3. HCV HCV Protease Nucleoside Antimetabolite/Analog
  4. Valopicitabine

Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Valopicitabine dihydrochloride) usually boasts enhanced water solubility and stability.

Para uso exclusivo en investigación. No vendemos a pacientes.

Valopicitabine

Valopicitabine Estructura química

No. CAS : 640281-90-9

Tamaño Stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  
250 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Valopicitabine:

Other Forms of Valopicitabine:

Valopicitabine Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination[1][2].

IC50 & Target

HCV[1]
Cellular Effect
Cell Line Type Value Description References
Huh-7 CC50
>100 3
Compound: valopicitabaine
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
[PMID: 17521911]
Huh-7 CC50
> 100 3
Compound: valopicitabaine
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
[PMID: 17521911]
Huh-7 CC50
>100 3
Compound: 1
Cytotoxicity against human HuH7 cells assessed as cell viability
Cytotoxicity against human HuH7 cells assessed as cell viability
[PMID: 19493593]
Huh-7 EC50
1.5 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
7.45 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
7.45 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
1.5 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
7.6 3
Compound: 1
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
[PMID: 19493593]
Huh-7 EC50
7.6 3
Compound: 1
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
[PMID: 19493593]
Huh-7 CC50
> 100 3
Compound: 1
Cytotoxicity against human HuH7 cells assessed as cell viability
Cytotoxicity against human HuH7 cells assessed as cell viability
[PMID: 19493593]
Huh-7 CC50
> 100 3
Compound: valopicitabaine
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
Cytotoxicity against Huh7 cells after 24 hrs by MTS assay
[PMID: 17521911]
Huh-7 EC50
1.5 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
7.45 3
Compound: valopicitabaine
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay
[PMID: 17521911]
Huh-7 EC50
7.6 3
Compound: 1
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
Antiviral activity against HCV infected in human HuH7 cells by cell-based subgenomic replicon assay
[PMID: 19493593]
In Vivo

Valopicitabine (NM283) (100 mg/kg; oral administration; Sprague-Dawley Rats) shows the Cmax, AUC, t1/2, and tmax were 3.624 μg/mL, 8.95 μg h/mL, 0.64 hours and 1 hour, respectively[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
Peso molecular

356.37

Fòrmula

C15H24N4O6
No. CAS
SMILES

C[C@@]1([C@@](N2C(N=C(C=C2)N)=O)([H])O[C@@H]([C@H]1OC([C@@H](N)C(C)C)=O)CO)O
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Valopicitabine Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Valopicitabine640281-90-9NM283NM 283NM-283HCVHCV ProteaseNucleoside Antimetabolite/AnalogHepatitis C virusprodrugoralnucleosideanalogchainterminationpolymeraseInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Valopicitabine
Cat. No.:
HY-108060
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.